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ABSTRACT
We have previously shown that IFIT1 is primarily responsible for the antiviral action of interferon (IFN) alpha/beta against
parainfluenza virus type 5 (PIV5), selectively inhibiting the translation of PIV5mRNAs. Here we report that while PIV2, PIV5,
andmumps virus (MuV) are sensitive to IFIT1, nonrubulavirus members of the paramyxoviridae such as PIV3, Sendai virus
(SeV), and canine distemper virus (CDV) are resistant. The IFIT1 sensitivity of PIV5 was not rescued by coinfection with an
IFIT1-resistant virus (PIV3), demonstrating that PIV3 does not specifically inhibit the antiviral activity of IFIT1 and that the
inhibition of PIV5 mRNAs is regulated by cis-acting elements. We developed an in vitro translation system using purified hu-
man IFIT1 to further investigate the mechanism of action of IFIT1.While the translations of PIV2, PIV5, andMuVmRNAs were
directly inhibited by IFIT1, the translations of PIV3, SeV, and CDVmRNAs were not. Using purified humanmRNA-capping
enzymes, we show biochemically that efficient inhibition by IFIT1 is dependent upon a 5= guanosine nucleoside cap (which need
not be N7methylated) and that this sensitivity is partly abrogated by 2=Omethylation of the cap 1 ribose. Intriguingly, PIV5M
mRNA, in contrast to NPmRNA, remained sensitive to inhibition by IFIT1 following in vitro 2=Omethylation, suggesting that
other structural features of mRNAsmay influence their sensitivity to IFIT1. Thus, surprisingly, the viral polymerases (which
have 2=-O-methyltransferase activity) of rubulaviruses do not protect these viruses from inhibition by IFIT1. Possible biological
consequences of this are discussed.
IMPORTANCE
Paramyxoviruses cause a wide variety of diseases, and yet most of their genes encode structural proteins and proteins involved in
their replication cycle. Thus, the amount of genetic information that determines the type of disease that paramyxoviruses cause
is relatively small. One factor that will influence disease outcomes is how they interact with innate host cell defenses, including
the interferon (IFN) system. Here we show that different paramyxoviruses interact in distinct ways with cells in a preexisting
IFN-induced antiviral state. Strikingly, all the rubulaviruses tested were sensitive to the antiviral action of ISG56/IFIT1, while all
the other paramyxoviruses tested were resistant. We developed novel in vitro biochemical assays to investigate the mechanism of
action of IFIT1, demonstrating that the mRNAs of rubulaviruses can be directly inhibited by IFIT1 and that this is at least par-
tially because their mRNAs are not correctly methylated.
Paramyxoviruses are a large group of negative-sense single-stranded RNA viruses that cause a wide variety of animal and
human diseases. The Paramyxoviridae family is divided into two
subfamilies, the Paramyxovirinae and the Pneumovirinae subfam-
ilies. The Paramyxovirinae are further subdivided into a number
of genera, including Morbillivirus (e.g., Measles virus [MeV] and
Canine distemper virus [CDV]), Respirovirus (e.g., Sendai virus
[SeV] and Parainfluenza virus type 3 [PIV3]), and Rubulavirus
(e.g.,Mumps virus [MuV], PIV2, and PIV5). Paramyxoviruses are
enveloped viruses; the viral glycoproteins protrude from the outer
surface of the envelope and function to attach the viruses to their
target cells. On the inner surface of the envelope is the matrix (M)
protein, which is required for the structural integrity of the virion.
The envelope surrounds a helical nucleocapsid, in which the nu-
cleocapsid protein (NP) encapsidates genomic or antigenomic
RNA. Associated with the nucleocapsid is the virally encoded
polymerase complex. The viral polymerase both transcribes and
replicates the viral genome.ViralmRNAs are capped andpolyade-
nylated by the viral polymerase (for reviews of the molecular bi-
ology of paramyxoviruses, see references 1 and 2).
Despite their limited genetic information, the majority of
paramyxoviruses encode smallmultifunctional accessory proteins
that function to aid virus multiplication and block cellular antivi-
ral defense mechanisms; typically, these proteins can block both
the production of, and the signaling response to, interferons
(IFNs) (for reviews, see references 3, 4, 5, 6, and 7). Significantly,
the mechanisms of action of these multifunctional IFN antago-
nists differ from one virus to another. Undoubtedly, these prop-
erties and in general the manner in which paramyxoviruses inter-
act with the IFN system and other innate defense mechanisms are
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likely to be major factors in determining the type of disease that
each virus causes (8).
The IFN response is an extremely powerful antiviral defense
system that, unless counteracted by viruses, will limit their repli-
cation to such a degree that they will not cause disease or be effi-
ciently transmitted between susceptible hosts (8, 9). Infected cells
detect the presence of viruses due to the production by viruses
of molecules with molecular signatures (pathogen-associated
molecular patterns [PAMPs]) such as double-stranded RNA
(dsRNA), which activate the IFN induction cascade and result in
the secretion of IFN-/ from infected cells (9, 10). The release of
IFN induces an antiviral state in neighboring uninfected cells by
upregulating the expression of hundreds of interferon-stimulated
genes (ISGs), many of which have direct or indirect antiviral ac-
tivity (11). Most paramyxoviruses counteract the IFN responses
by producing proteins that block IFN induction and/or IFN sig-
naling by a variety ofmechanisms (3–7). Furthermore, they tightly
control viral transcription and replication, thereby limiting the
production of PAMPs thatmay activate the IFN response (12, 13).
Indeed, it is probablymistakes that virusesmake during transcrip-
tion and replication, such as the production of copy-back-defec-
tive interfering particles, that activate the IFN response (14–16;
reviewed in reference 17). Nevertheless, the ability of paramyxo-
viruses to block the IFN response both in tissue culture cells and in
vivo is not absolute, and some IFN-/ will be produced (18, 19).
Furthermore, IFN-, which can also induce an antiviral state in
cells, will also be produced by activated subsets of lymphocytes
(20). Therefore, it is inevitable that viruses will infect cells in a
preexisting IFN-induced antiviral state, potentially limiting the
speed of virus replication and spread. Although IFNs induce hun-
dreds of ISGs, several ISGs with direct antiviral activity have been
shown to be specific for families or groups of related viruses (11,
21, 22). With regard to the Paramyxoviridae family, we have pre-
viously shown that ISG56/IFIT1 (here referred to as IFIT1), which
selectively inhibits translation, is the primary effector of the IFN-
induced antiviral state that limits the replication of the rubulavi-
rus PIV5 (23). Pretreatment of cells with IFN-/ inhibits PIV5
protein synthesis but not cellular protein synthesis. This is because
IFIT1 selectively inhibits the translation of PIV5mRNAs but does
not affect cellular mRNAs (23).
Mammalian mRNAs have an N-7 methyl guanosine
(m7GpppN), termed cap 0, at their 5= end that recruits factors
involved in RNA processing and translation initiation. The first
and second nucleosides of mammalian mRNAs are also methyl-
ated on the 2= hydroxyl group of the ribose ring, generating cap 1
and cap 2, respectively. While cap 1 and cap 2 are not required for
efficient mRNA translation, IFIT1 can inhibit the translation of
mRNAs that lack cap 1 (24–27). IFIT1 also binds uncapped, 5=-
triphosphorylated RNA, characteristic of the 5= ends of the
genomic and antigenomic RNAs of some RNA viruses, as well as
those of some viral transcripts (28); for reviews on themechanism
of action of IFIT1 and the IFIT family of proteins, see references
21, 26, 27, and 29. However, recent evidence suggests that there
are differences in the mechanisms of action of the murine and
human paralog IFIT1 proteins. While murine IFIT1 (IFIT1B) in-
hibits the translation of mRNAs that lack cap 1, it has been pro-
posed that human IFIT1 recognizes some other, as-yet-undefined
structure near the cap or possibly that 5= mRNA sequences may
help define the specificity of inhibition by human IFIT1 (30). The
RNA-capping activity of viral RNA polymerases often include 2=-
O-methyltransferases (2=-O-MTases), which modify cap 1 and
thus can avoid inhibition by IFIT1(B), as evidenced by the sensi-
tivity of virus mutants that lack 2=-O-MTase activity (for reviews,
see references 21 and 26). Capping andmethylation of viral RNAs
are also important, as such modifications can prevent the activa-
tion of RIG-I, thereby reducing the amount of IFN produced by
virally infected cells (for a review, see reference 31).
Herewe have examined the ability of IFIT1 to inhibit the trans-
lation of a variety of paramyxovirus mRNAs and thus the replica-
tion of those viruses. We show that while all rubulaviruses tested
were sensitive to IFIT1, all nonrubulavirus members of the
Paramyxoviridae testedwere insensitive. Lack of 2=O-methylation
of rubulavirus mRNAs was at least partially responsible for their
inhibition by IFIT1. The possible biological consequences of dif-
ferences in sensitivity of paramyxoviruses to IFIT1 are discussed.
MATERIALS AND METHODS
Cells, viruses, antibodies, and interferon.A549 cells andderivativeswere
grown as monolayers in 25-cm2, 75-cm2, or 300-cm2 tissue culture flasks
in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
bovine serum at 37°C. When appropriate, cells were treated with human
recombinant interferon (Intron A; Merck, Sharpe and Dohme) at 1,000
units/ml. Viruses used in these studies were PIV2 (strain Colindale), PIV3
(strainsWashington and JS and recombinantC andD JS viruses [32]),
PIV5 (formerly known as SV5; strainsW3 [33] and CPI and CPI [34]),
MuV (Enders [35]), respiratory syncytial virus (RSV) (36), Sendai virus
(strain Cantell, free of defective interfering particles), and canine distem-
per virus (strain Mill Hill). Plaque assays were performed by standard
methods in six-well dishes that included 0.1% Avicel (FMC Biopolymer)
in the overlay medium. Plaques were visualized by immunostaining by
using a pool of monoclonal antibodies or polyclonal antisera specific for
the different viruses as described previously (37), together with alkaline
phosphatase-conjugated secondary antibody by using SigmaFast BCIP/
NBT as the substrate.
Preparation of L-[35S]methionine-labeled total-cell extracts and
SDS-PAGE. Infected or uninfected cells that had or had not been pre-
treated with IFN for 12 h prior to infection were metabolically labeled for
1 h with L-[35S]methionine (500 Ci/mmol; MP Biomedical, USA) at 18 h
postinfection (p.i.). After labeling, cells were lysed in disruption buffer,
sonicated, and heated for 5 min at 100°C and then analyzed by gel elec-
trophoresis (SDS-PAGE). The gels were fixed, stained, and dried, and
resolved bandswere visualized by phosphorimager analysis.When appro-
priate, the same amounts of cell equivalents were run on PAGE. Further-
more, the amount of protein in each sample was monitored by staining
the polyacrylamide gels (PAGs) with Coomassie brilliant blue.
Immunofluorescence. Cells to be stained for immunofluorescence
were grown on 10-mm-diameter coverslips (MIC3270; Scientific Labora-
tory Supplies, United Kingdom). Cells were stained with specific mono-
clonal antibodies (MAbs), as described in detail elsewhere (38). Briefly,
monolayers were fixed with 5% formaldehyde–2% sucrose in phosphate-
buffered saline (PBS) for 10 min at 20°C, permeabilized with 0.5% Non-
idet P-40–10% sucrose in PBS for 5 min at 20°C, and washed three times
in PBS containing 1% calf serum. PIV5- and PIV3-infected cells were
detected by indirect immunofluorescence using a secondary goat anti-
mouse Ig Texas Red-conjugated antibody (catalog number ab6787;
Abcam). The primary antibodies were PIV5-NP-a and PIV5-Pe for PIV5
(39) and 4721, 2281, and 4812 for PIV3 (40). After staining for immuno-
fluorescence, the monolayers of cells were examined with a NikonMicro-
phot-FXA immunofluorescence microscope.
RNA selection and in vitro translation. RNA for in vitro translations
was isolated by sedimentation through CsCl gradients by a modified
methoddescribed by Leppert et al. (41). Confluentmonolayers of infected
cells, grown in 300-cm2 flasks, were resuspended in ice-cold lysis buffer
(150 mM NaCl, 50 mM Tris-HCl [pH 7.5], 0.6% NP-40, protease inhib-
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itor cocktail [complete Mini EDTA-free, 1 tablet per 7 ml of buffer;
Roche]) at 1 108 to 2 108 cells per ml and left on ice for 5 min prior
to vortexing for 2 min. Nuclei were removed by centrifugation twice at
4,200  g for 5 min at 4°C. The supernatant (cytoplasmic extract) was
collected,made up to 6mMEDTA, and layered onto 35% (wt/wt) CsCl in
25 mM Tris-HCl (pH 7.5)–2 mM EDTA followed by centrifugation at
175,000 g at 12°C for 16 to 18 h. Naked RNA (including mRNA) forms
a pellet at the bottom of the gradient, while viral genomic and antigeno-
mic RNAs remain complexed with nucleoprotein and do not enter the
35% CsCl cushion. The supernatant was discarded, and the pellet was
resuspended in RNase-free water and adjusted to 1 	g/	l. Selected RNA
was translated in vitro with a rabbit reticulocyte lysate kit (L4960; Pro-
mega) in the presence of [35S]methionine-cysteine (NEG772, EasyTag
Express Protein Labeling mix; PerkinElmer) using a modification to the
manufacturer’s instructions: methionine-cysteine-free medium (D0422;
Sigma) was used to provide other amino acids (1 	l per 50 	l reaction
mixture).
Capping and methylation of mRNA. Human RNA guanylyltrans-
ferase and 5=-phosphatase (RNGTT), RNA guanine-7 methyltransferase
(RNMT), and cap methyltransferase 1 (CMTR1) were synthesized and
purified according to the method of Gonatopoulos-Pournatzis et al. (42).
As described in that study, the enzymes were all verified as being active by
in vitro reactions followed by thin-layer chromatography. Capping and
methylation reactions were carried out in 50 mM Tris-HCl (pH 8.0), 6
mM KCl, 1.25 mM MgCl2, 1 mM dithiothreitol (DTT) buffer as follows:
1 	l 10 buffer, 1 	l RNGTT (2.5 mg/ml), 1 	l RNMT (0.5 mg/ml),
CMTR1 (0.28 mg/ml), 1 	l SAM (2 mM), 1 	l GTP (1 mM), 0.5 	l
RNasin, 2 	l RNA (1 	g/	l). The reaction mixture was made up to 10 	l
with H2O, including in experiments in which RNGTT, RNMT, or
CMTR1 was omitted, and incubated at 37°C for 1 h.
Cloning and purification of IFIT1. IFIT1 was amplified with primer
IFIT1F/IFIT1Xho from the plasmid pGAC-HA-IFIT1, restricted with
NcoI and XhoI, and ligated with a modified pLOU3, in which maltose
binding protein (MPB) was replaced with SUMO, while SalI in the mut-
liple cloning site (MCS) was replaced with XhoI. The primers were as
follows: IFIT1F, CCGCCATGGCTACAAATGGTGATGATCATCAGG;
IFIT1Xho, GCGCCTCGAGCTAAGGACCTTGTCTCACAGAGTT.
The fusion protein His-SUMO-(TEV)-IFIT1 was expressed in Esche-
richia coli strain Rosetta in 6 liters LB-ampicillin-chloramphenicol (LB/
Amp/CM). Isopropyl--D-thiogalactopyranoside (IPTG; 0.2 mM) was
added when an optical density (OD) of 0.8 was reached. The expression
was carried out at 18°C overnight.
Purification was carried out with a routine protocol for His-tagged
protein. The binding buffer contained 20 mM Tris-HCl (pH 8.0), 0.3 M
NaCl, and 10 mM imidazole; the washing buffer contained 30 mM imi-
dazole; and protein was eluted with 300 mM imidazole. To remove non-
specifically bound RNA, the columns were washed with 9 volumes of 0.2
M Na2HPO4–4 MNaCl (pH 7.5). After desalting into GF buffer (20 mM
Tris-HCl [pH 8], 150mMNaCl, 5% glycerol), the fusionwas cleavedwith
tobacco etch virus (TEV) protease (1:100) at room temperature over-
night. Gel filtration was carried out after passing through Ni beads again
and addition of 3 mM DTT. The IFIT1 peak was collected and concen-
trated and had an A260/A280 of 0.7 to 0.8.
RESULTS
Paramyxoviruses interact in distinct ways with cells in a pre-
existing IFN-induced antiviral state. Despite the fact that
paramyxoviruses encode IFN antagonists that inhibit IFN pro-
duction and signaling, their ability to block the IFN response is not
absolute. Thus, they form larger plaques on IFN-incompetent
cells than IFN-competent cells (Fig. 1) (19), showing that dur-
ing virus replication and spread some IFN is produced and
slows the spread of the viruses (see Fig. 3). In the experiments
FIG 1 A549 cells produce and respond to IFN during development of PIV2, PIV3, and PIV5 plaques. (a) A549 cells grown on coverslips in 24-well microtiter
plates were infected with PIV2, PIV3, or PIV5 at an MOI that resulted in 2 to 10 plaques per well. At 3 days p.i., the cells were fixed and stained with antibodies
to the NP proteins of the respective viruses (green) and anti-MxA antibody, which is an ISG that is upregulated in response to IFN-/ (red). The images show
cross sections through plaques with the center of the plaque at the left-hand side of the image. (b) Relative plaque sizes of PIV2 (Colindale), PIV3 (Washington
strain), and PIV5 (W3) on A549, A549/shIFIT1, and A549/NPro cells. Infected monolayers of cells in 6-well dishes were fixed at 4 days (PIV3) or 5 days (PIV2
and PIV5) p.i., and virus plaques were visualized by immunostaining themonolayers with antibodies to the respective NP and/or P proteins. The numbers at the
bottom right in each panel give the average plaque sizes in millimeters with their standard deviations.
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shown in Fig. 1 and below, we used naive A549, A549/Npro,
and A549/shIFIT1 cells; naive A549 cells can produce and re-
spond to IFN in response to virus infection, and A549/Npro
cells respond to exogenous IFN but cannot produce IFN as they
constitutively express Npro from bovine viral diarrhea virus
(BVDV), which targets IRF-3 for degradation (43). Further-
more, because IRF-3 is degraded in A549/Npro cells, they can-
not upregulate expression of IFIT1 in an IRF-3-dependent,
IFN-independent manner in direct response to virus infection
(29). A549/shIFIT1 cells produce and respond to IFN, but ex-
pression of endogenous IFIT1 in response to IFN or viral in-
fection is inhibited due to constitutive expression of small hair-
pin RNA (shRNA) to IFIT1 (23).
We previously showed that IFIT1 is the major cellular protein
responsible for the IFN sensitivity of the rubulavirus PIV5 (23). To
further investigate the role of IFIT1 and the ability of IFN to in-
duce an antiviral state against other paramyxoviruses, we initially
tested the ability of PIV2, PIV3, andPIV5 to formplaques inA549,
A549/Npro, andA549/shIFIT1 cells. All three viruses induced IFN
in A549 cells as the plaques developed, as observed by the induc-
tion of MxA in the uninfected cells surrounding the plaque (Fig.
1a). As previously observed (23), PIV5 formed bigger plaques on
A549/shIFIT1 cells than on A549 cells, but the plaques were not as
large as those on A549/Npro cells (Fig. 1b). While PIV2 also pro-
duced slightly larger plaques on A549/shIFIT1 than on A549 cells,
the plaques on A549/Npro cells were obviously bigger (note that
the center of mid- to large-sized PIV2 plaques has fallen out of
monolayers). PIV3 produced similarly sized plaques on A549 and
A549/shIFIT1 cells and slightly larger plaques onA549/Npro cells.
These results also support our previous conclusion that in A549
(and Hep2) cells IFIT1 is the primary ISG effector to PIV5 (23)
and that the rubulavirus PIV2 is also sensitive to IFIT1. However,
knocking down IFIT1 did not have such a marked effect on PIV2
plaque size as it did for PIV5. This indicates that there are likely to
be additional ISGs that play an important role in IFN-mediated
inhibition of PIV2. In contrast, PIV3 (Washington strain) pro-
duced similarly sized plaques onA549 andA549/shIFIT1 cells and
only slightly larger plaques on A549/Npro cells; this suggests that
the IFN response is capable of slowing the spread of PIV3 to some
degree (but not through the activity of IFIT1), but not as dramat-
ically as it does for PIV2 or PIV5. However, experiments on the JS
strain of PIV3 showed it to bemore sensitive to the antiviral effects
of IFN, but this was not because JS is sensitive to IFIT1 (data not
shown).
We next compared the synthesis of viral proteins in cells in-
fected with PIV2, PIV3, and PIV5 that had, or had not, been pre-
treated with IFN prior to infection with PIV2, PIV3, and PIV5.
Cells were infected at a high multiplicity of infection (MOI; 10 to
20 PFU/cell), and the relative levels of NP synthesis were visual-
ized by radioactively labeling the cells for 1 hwith [35S]methionine
at 18 h p.i. (Fig. 2). Pretreatment of A549 and A549/Npro cells
with IFN in this assay reduced the expression of the NP of PIV2
and PIV5 to barely detectable levels. However, IFN pretreatment
had no discernible effect on the expression of the NP protein of
PIV3 or on the expression of host cell proteins. Strikingly, expres-
sion ofNPof PIV2 andPIV5was largely rescued in IFN-pretreated
A549/shIFIT1 cells, demonstrating that IFIT1 plays amajor role in
the inhibition of PIV2 and PIV5 protein synthesis observed in
A549 and A549/Npro cells pretreated with IFN. Figure 2 is an
exemplar of many similar experiments that we have performed
under different conditions (time course,MOI, etc.) and that show
the same results, namely, that PIV2 and PIV5 are inhibited by
IFIT1 while PIV3 is not.
Having demonstrated that PIV2 and PIV5 are sensitive to
IFIT1 while PIV3 is resistant, we tested the sensitivity of other
members of the Paramyxoviridae family, namely, mumps virus
(MuV strain Enders), Sendai virus (SeV), and canine distemper
virus (CDV). In a set of experiments similar to those illustrated in
Fig. 2, A549/Npro and A549/shIFIT1 cells were or were not pre-
treated with IFN prior to infection with high MOI with these vi-
ruses. The relative levels of NP synthesis were visualized by radio-
actively labeling the cells for 1 h with [35S]methionine at 18 h p.i.
(Fig. 3A). These experiments clearly demonstrated that, as was
observed for PIV2 and PIV5, pretreating A549 cells with IFN in-
hibited MuV strain Enders protein synthesis but knocking down
IFIT1 expression could largely restore MuV protein synthesis. In
contrast, aswas observed for PIV3, althoughpretreatment ofA549
cells with IFN slightly reduced the expression of SeV and CDV
FIG 2 IFIT1 inhibits PIV5 (W3) and PIV2 (Colindale) protein synthesis but not that of PIV3 (Washington). A549, A549/NPro, and A549/shIFIT1 cells, grown
in 25-cm2 flasks were, or were not, treated with IFN 8 h prior to infection at a high MOI with PIV2, PIV3 (Washington strain), or PIV5. At 18 h p.i., cells were
metabolically labeled with [35S]methionine for 1 h. Total-cell extracts were separated by electrophoresis through a 4 to 12% PAG, and labeled proteins were
visualized using a phosphorimager. The positions of the NP polypeptides are indicated by asterisks. The values at the bottom indicate the fraction of NP made
in cells pretreated with IFN compared to untreated cells as estimated by densitometry scans.
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protein synthesis, no increase in SeV and CDV protein synthesis
was observed in A549/shIFIT1 compared to A549 cells pretreated
with IFN. These results therefore show that MuV Enders is sensi-
tive to IFIT1 but SeV and CDV are not, the weak inhibition of SeV
and CDV protein synthesis observed in A549 and A549/shIFIT1
cells pretreated with IFN presumably being due to the action of
other ISGs induced by IFN. While MuV is sensitive to IFIT1, it
forms pinpoint plaques on A549/Npro cells only at 5 days p.i.
(data not shown), strongly suggesting that there are host cell re-
strictions other than innate intracellular defense mechanisms on
MuV replication in A549 cells (44).
Since in these experiments we used the attenuated Enders
strains of MuV to test whether attenuation may be linked to sen-
sitivity to IFIT1, we tested a wild-type (wt) isolate of MuV-Lon-
don-1 (Lo-1) for its sensitivity. At the same time, we also tested the
sensitivity of another strain of PIV5, termed CPI (Fig. 3B).
MuV-Lo was as sensitive as MuV Enders, demonstrating that at-
tenuation was not linked to differences in their relative sensitivity
to IFIT1. Similarly, PIV5 CPI was also sensitive to inhibition by
IFIT1.
The IFIT1 sensitivity of PIV5 is not rescued by coinfection
with an IFIT1-resistant virus. From these results, it was clear that
replication of the nonrubulaviruses PIV3, SeV, and CDV is not
inhibited by IFIT1. To investigate whether PIV5 replication could
be rescued by coinfections with an IFIT1-resistant virus, mixed
infections between PIV3 and PIV5were undertaken. To avoid any
possible synergistic effects between PIV3 and PIV5 in dismantling
an IFN-induced antiviral state, the CPI strain of PIV5 was used
in these experiments because, due to mutations in its V protein, it
does not block IFN signaling (45). A549 or A549/shIFIT1 cells
were or were not pretreated with IFN for 8 h prior to high-MOI
(10 to 20 PFU/cell) infection with PIV5, PIV3, or a mixture of the
two viruses (Fig. 4a). The expression of the NP protein of PIV3
was resistant to IFN in both A549 and A549/shIFIT1 cells when
they were infected with PIV3 alone and when coinfected with
PIV5. In contrast, while the expression of PIV5NPwas resistant to
IFN in A549/shIFIT1 cells, its expression was inhibited in A549
cells, even when the cells were coinfected with PIV3. Immunoflu-
orescence was undertaken to ensure that in these experiments
there was no exclusion of one virus by the other (Fig. 4b and c).
FIG 3 IFIT1 inhibits MuV (strain Enders and wild-type strain [Lo-1]) and
PIV5 (strain CPI) protein synthesis but not that of SeV or CDV. A549/NPro
cells and A549/shIFIT1 cells, grown in 25-cm2 flasks, were or were not treated
with IFN 8 h prior to infection at a high MOI with MuV Enders, MuV Lo-1
(wt), SeV, CDV, or PIV5 (CPI). At 18 h p.i., cells were metabolically labeled
with [35S]methionine for 1 h. Total-cell extracts were separated by electropho-
resis through a 4 to 12% PAG, and labeled proteins were visualized using a
phosphorimager. The values at the bottom indicate the fraction of NPmade in
cells pretreated with IFN to NP made in untreated cells.
FIG 4 PIV3 (Washington) does not inhibit the antiviral activity of IFIT1. A549 and A549/shIFIT1 cells, grown in either 25-cm2 flasks (a) or on coverslips (b and
c), were or were not treated with IFN 8 h prior to infection at a highMOI with PIV3, PIV5 (strain CPI), or a mixture of the two viruses. (a) At 18 h p.i., the cells
weremetabolically labeled with [35S]methionine for 1 h. Total cell extracts were separated by electrophoresis through a 4 to 12% PAG, and labeled proteins were
visualized using a phosphorimager. The positions of the NP protein are indicated by asterisks. (b and c) At 18 h p.i., cells grown on coverslips were fixed and
immunostained with antibodies specific for the NP and/or P proteins of the respective viruses.
Young et al.
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These results confirmed that coinfection of PIV3 with PIV5 does
not rescue the sensitivity of PIV5 to IFIT1 and strongly suggest
that PIV3 does not specifically inhibit the antiviral activity of
IFIT1 and that the inhibition of PIV5 NP expression is regulated
by cis-acting elements.
Differential inhibition of translation of mRNAs of different
paramyxoviruses by purified IFIT1. The data above show that
the IFN sensitivity of rubulaviruses is at least in part due to the
actions of IFIT1. Since this cellular protein has been shown to
inhibit translation in a template-specificmanner, we developed an
in vitro translation system to study the ability of human IFIT1 to
selectively inhibit the translation of rubulavirusmRNAs. The gene
encoding human IFIT1 was cloned as a SUMO fusion protein
expressed in Escherichia coli, and the recombinant protein was
purified (Fig. 5a). To determine whether the recombinant IFIT1
was able to selectively inhibit PIV5 mRNAs, in vitro translation of
mRNA isolated from mock- and PIV5-infected cells was carried
out in the presence and absence of different concentrations of
IFIT1 (Fig. 5b, c, and d). In the absence of IFIT1, expression of the
NP protein (and to a lesser extent the M protein) of PIV5 was
clearly visualized in the background of in vitro-translated cellular
proteins (Fig. 5c and d). Increasing concentrations of IFIT1 had
no obvious effect on the efficiency of translation of host cell pro-
teins, but in striking contrast, purified IFIT1 selectively inhibited
the translation of the NP and M proteins of PIV5 in a concentra-
tion-dependent manner.
Having established that the sensitivity of in vitro translation of
PIV5 mRNA to inhibition by purified IFIT1 correlated with the
biological sensitivity of PIV5 to IFIT1, we next tested the ability of
IFIT1 to inhibit the translation of mRNA isolated from cells in-
fected with other paramyxoviruses (Fig. 6). These results clearly
demonstrated that translation of (NP) mRNAs from PIV2- and
fromMuV-infected cells was inhibited by IFIT1. In contrast, there
was no obvious reduction in the amount of PIV3 NP synthesized
when increasing amounts of IFIT1 was added to the in vitro trans-
lation reaction mixtures. Although there was a slight apparent
reduction in the amount of SeV and CDV NP synthesis in the
samples in which IFIT1 was added, there was no increase in the
inhibition observed by increasing the amount of IFIT1 added to
the in vitro translation reaction mixtures, strongly suggesting that
the translations of SeV and CDV mRNAs are also resistant to
inhibition by IFIT1.
Lack of 2=-O methylation of the cap structure of MuV and
PIV5 mRNAs is partially responsible for their sensitivity to in-
hibition by IFIT1. Previous studies have shown that the absence
of cap 1 on mRNAs renders them sensitive to inhibition to IFIT1.
To investigate whether this was the case for rubulavirus mRNAs,
we developed an in vitro assay in which purified human mRNA-
modifying enzymes were used to progressively cap and add differ-
entmethyl groups to the 5= ends ofmRNAs. Purified human RNA
guanylyltransferase and 5=-phosphatase (RNGTT), RNA gua-
nine-7 methyltransferase (RNMT), and cap methyltransferase 1
(CMTR1) were used in these assays. RNGTT adds a 5= guanosine
to RNAs with 5=-ppp, while RNMT adds a methyl group to the 7G
of the guanine ring, generating (m7G) cap 0. CMTR1 adds a
methyl group to the 2= OH position of the adjacent ribose, gener-
ating cap 1. To demonstrate the functionality of this system, we
first tested the in vitro translation of luciferase mRNA with a 5=-
triphosphate group. This RNA was efficiently translated in a cap-
independent manner and was only weakly inhibited by IFIT1
FIG 5 Purified IFIT1 directly inhibits in vitro translation of PIV5mRNA. (a) Coomassie brilliant blue-stained PAG of purified IFIT1; molecular weight markers
are shown in the left-hand lane. (b and c) RNA isolated frommock- or PIV5-infected cells was in vitro translated in the presence of [35S]methionine for 90 min
in the presence or absence of increasing concentrations of purified IFIT1 (0.1 and 1.0 	g per reaction mixture). Polypeptides were separated by electrophoresis
through a 4 to 12% PAG. The total protein contents present in the in vitro translation mixes were visualized by staining the gel with Coomassie brilliant blue
(b), and the radioactively labeled proteins were visualized using a phosphorimager (c). (d) Densitometry traces of lanes 1, 3, 4, and 6 of panel c. The
positions of PIV5 NP and M proteins are indicated; asterisks mark two prominent host cell polypeptides. The values at the bottom of the gel indicate the
fraction of either the host cell proteins or NP proteins made in the in vitro translation mixes in the presence of purified IFIT1 compared to those made in
the absence of IFIT1.
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(Fig. 7a, compare lanes 1 and 2). When the luciferase mRNA was
capped with the addition of 5=-guanosine by RNGTT (generating
Gppp-mRNA), there was a slight decrease in the amount of lucif-
erase made (Fig. 7a, compare lanes 1 and 3). This may have been
due to RNGTT destabilizing or blocking the translation of Gppp-
mRNAs in the absence of 7N methylation. However, strikingly,
translation of this mRNA was completely inhibited by IFIT1 (Fig.
7a, lane 4) despite this cap structure lacking N-7 methylation. As
expected, the addition of amethyl group to theN-7 position of the
guanine ring, generating m7Gpppm2N, by RNMT increased the
efficiency of translation, but m7Gppp-luciferase remained com-
pletely sensitive to inhibition by IFIT1 (Fig. 7a, lanes 5 and 6).
Addition of a methyl group to the 2= OH group of the adjacent
ribose, generating cap 1, by CMTR1 did not affect the efficiency
by which the mRNAwas translated, but it did clearly reduce the
sensitivity of the mRNA to inhibition by IFIT1 (Fig. 7A, com-
pare lanes 7 and 8). However, it should be noted that in these
experiments, for reasons that are unclear, we were unable to
completely restore full translation of the luciferase mRNA in
the presence of IFIT1 by increasing the amount of CMTR1 or
the length of incubation of the mRNA with the enzyme (data
not shown).
To investigate how similar modifications to the cap of rubula-
virus mRNAs influenced their inhibition by IFIT1, we initially
used MuV mRNA in a parallel set of experiments. These results
showed that treatment of the MuV mRNA with RNGTT and
RNMT did not increase the efficiency of in vitro translation of
MuV NP mRNA or its sensitivity to inhibition by IFIT1 (Fig. 7b,
lanes 1 to 6), consistent with the viral polymerase adding
m7Gppp-cap at (cap 0) to the 5= end of viral mRNAs. However,
surprisingly, since rubulavirus polymerases have conserved 2=-O
MTase domains, addition of amethyl group to the 2=OH group of
the adjacent ribose (cap 1) by CMTR1 clearly reduced the sensi-
tivity of the NPmRNA to inhibition by IFIT1 (Fig. 7b, lanes 7 and
8). As expected, the IFIT1 sensitivity was dependent on the addi-
tion of S-adenosyl methionine (SAM) to the reaction mixture
(Fig. 7c). Similarly, following 2=Omethylation of PIV5 mRNA, in
vitro translation of PIV5 NP became completely resistant to inhi-
bition by IFIT1 (Fig. 7d). Strikingly, in contrast to NP, the trans-
lation of PIV5MmRNA remained completely sensitive to inhibi-
tion by IFIT1 even after 2=O methylation of PIV5 mRNA by
CMTR1 (Fig. 7d and e); the basis for this is currently unknown,
but we are investigating it further.
DISCUSSION
Over the past decade or so, it has become clear that the ways in
which paramyxoviruses circumvent innate immune responses,
including the IFN response, and differences in themultifunctional
nature of their IFN antagonists are likely to influence the types of
disease they cause. For example, the viral IFN antagonists within
the rubulavirus genus, namely, the V proteins, as well as interact-
ing with common targets such as MDA 5 and LGP2 also have
unique properties. The V protein of PIV5 targets STAT1 for deg-
radation, PIV2 targets STAT2, and MuV targets both STAT1 and
STAT3. Within the Respirovirus and Morbillivirus genera, it is a
combination of the V and C proteins that counteract innate re-
sponses by different molecular mechanisms, and strikingly, al-
though PIV3 encodes a C protein, it does not encode a functional
FIG 6 Purified IFIT1 inhibits the in vitro translation of NP mRNA isolated from PIV2- and MuV-infected cells but not mRNA frommock-infected cells or NP
mRNA isolated from PIV3 (Washington strain)-, SeV-, or CDV-infected cells. RNA isolated from mock-infected or infected cells was in vitro translated in the
presence of [35S]methionine for 90 min in the presence or absence of increasing concentrations of purified IFIT1 (0.1 and 1.0 	g per reaction mixture).
Polypeptides were separated by electrophoresis through a 4 to 12% PAG, and labeled proteins were visualized using a phosphorimager. The positions of the NP
proteins are indicated. The numbers at the bottom of the gel indicate the fraction of either the host cell proteins or NP proteins made in the in vitro translation
mixes in the presence of purified IFIT1 compared to those made in the absence of IFIT1.
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V protein. Despite encoding of these powerful IFN antagonists,
IFN is produced during virus spread both in tissue culture cells
and in vivo, and thus undoubtedly paramyxoviruses will, during
the course of an infection, infect cells in a preexisting IFN-induced
antiviral state. Here we show that different paramyxoviruses in-
teract in distinct ways with cells in a preexisting IFN-induced an-
tiviral state, and we suggest that this may influence the types of
diseases caused. Strikingly, in contrast to the sensitivity of rubula-
viruses to IFIT1, the other paramyxoviruses that we tested were
resistant, strongly suggesting that this might be a distinguishing
feature of rubulaviruses, although before this can be firmly con-
cluded the sensitivity ofmore species of paramyxoviruses to IFIT1
needs to be tested. Even within the Rubulavirus genus, it appears
that there may be differences in how members interact with cells
in an IFN-induced antiviral state. In A549 cells, IFIT1 primarily is
responsible for the IFN-induced antiviral state induced to counter
PIV5. However, although PIV2 is sensitive to IFIT1, there appear
to be other ISGs that have strong anti-PIV2 activity. This conclu-
sion comes from the observation that while there is a slight in-
crease in the size of PIV2 plaques onA549/shIFIT1 cells compared
to A549 cells, it is not as obvious as that observed for PIV5. Fur-
thermore, while plaques for PIV5 were smaller on A549/shIFIT1
cells than onA549/Npro cells, this difference was not asmarked as
that observed for PIV2. MuV strain Enders is also sensitive to
IFIT1, but there are clearly other major constraints on the growth
of MuV Enders in human cells, as the virus grows extremely
poorly in IFN-incompetent human cells but replicates to high
titers in Vero cells (44).
It is striking that only rubulaviruses are sensitive to the antiviral
activity of human IFIT1. Our data indicate that the inhibition of
rubulavirus mRNAs was produced by IFIT1 in a cis-linked man-
ner, implying that the restriction is associatedwith some feature of
FIG 7 Lack of 2=-O methylation of the cap 1 structure of MuV and PIV5 mRNAs is at least partially responsible for their sensitivity to inhibition by IFIT1. (a)
Uncapped 5=-pppmRNA encoding luciferase synthesized by T7 polymerase (provided as a control in the Promega in vitro translation kit) was translated in vitro
in a rabbit reticulocyte lysate in the absence or presence of purified IFIT1 (lanes 1 and 2). RNGTT was used to add a 5= guanine cap (lanes 3 and 4); then, RNMT
was used to methylate the cap at the N7 position (lanes 5 and 6), generating cap 0, and CMTR1 was used to methylate the adjacent ribose on the 2=OH position,
generating cap 1. ThemodifiedmRNAs were then in vitro translated in the absence (lanes 3, 5, and 7) or presence (lanes 4, 6, and 8) of IFIT1. (b) mRNA isolated
fromMuV-infected cells was treated in parallel under the same conditions as those described for panel a. (c and d) mRNA isolated from either MuV (Enders)-
or PIV5 (W3)-infected cells was in vitro translated prior to (lanes 1 and 2) or following (lanes 3 and 4) modification by CMTR1 in the presence or absence (lanes
5 and 6) of SAM. ThemRNAwas also translated in the absence (lanes 1, 3, and 5) or presence (lanes 2, 4 and 6) of purified IFIT1. (e) Densitometry traces of lanes
1, 2, 3, and 4 of panel d. The numbers at the bottom of the gel indicate the fraction of either the host cell proteins or NP proteins made in the in vitro translation
mixes in the presence of purified IFIT1 compared to those made in the absence of IFIT1.
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the mRNA sequence or structure. Since IFIT1 can selectively in-
hibit the translation of mRNAs that are incorrectly capped or not
methylated at the 2=OHgroup of the first ribose, i.e., cap 1 (24, 46,
47), it was likely that rubulaviruses have a structural motif in their
cap, not present or hidden in the mRNA of other paramyxovi-
ruses, that is recognized by IFIT1. To investigate this further, we
used purified human enzymes to modify the cap of mRNAs. As a
control for the activity of the enzymes, we used an uncapped 5=-
ppp mRNA that encodes luciferase. The 5=-ppp luciferase mRNA
translated in a cap-independent manner in vitro using rabbit re-
ticulocyte lysate, and this translation was only weakly inhibited by
purified IFIT1. While addition of a 5= guanosine nucleoside cap
slightly decreased the amount of luciferase synthesized, probably
because the enzyme RNGTT destabilizes the mRNA, addition of
the (unmethylated) guanosine nucleoside to the 5= end of the
mRNA significantly increased the sensitivity of the mRNA to in-
hibition by IFIT1. Furthermore, althoughmethylation of the gua-
nine ring at position N7 (m7GpppNp-RNA) by RNMT increased
the efficiency of translation of luciferase mRNA, it did not appear
to affect the sensitivity of inhibition by IFIT1. These results are
therefore consistent with the observation that human IFIT1 binds
with low affinity to 5=-ppp RNA but more avidly to cap 0 RNA
lacking 2= O methylation. Methylation at position N7 of the gua-
nine ring has also been reported to increase the affinity of binding
of IFIT1 (24); however, the observation here that Gppp-luciferase
is inhibited as efficiently as m7Gppp-luciferase suggests that the
methyl group does not play a central role in the inhibition of
mRNAs by IFIT1. In contrast, 2= O-methylation of the first ribose
by CMTR1 to generate cap 1 partially prevented IFIT1 from in-
hibiting the translation of the cap 0-modified mRNA. However,
even by increasing the amount of CMTR1 and the incubation
time, we were unable to completely restore full translational ac-
tivity of the luciferasemRNA. The reasons for this are unclear, but
it suggests that other structural features, for example, methylation
of the penultimate ribose to generate cap 2 or sequences at the 5=
endofmRNAs,may also influence inhibition by IFIT1, as has been
suggested by Daugherty et al. (30).
mRNAs isolated from PIV3-, SeV-, and CDV-infected cells
were not inhibited by IFIT1, and neither was the replication of
these viruses (Fig. 2 and 3). In contrast, 2= O-methylation of the
terminal ribose by CMTR1 of MuV mRNAs partially alleviated
inhibition of the NP mRNA by IFIT1. With regards to PIV5, our
previous studies suggested that PIV5 mRNAs were 2= O-methyl-
ated (23). Furthermore, we never observed complete IFIT1 inhi-
bition of PIV5 NP synthesis in vitro, suggesting that at least a
proportion of the PIV5 NP mRNA was correctly capped. How-
ever, the fact that treating PIV5mRNAs with CMTR1 rescued NP
synthesis in the presence of IFIT1 suggests that a significant pro-
portion of PIV5mRNAs was also not fully methylated. It is also of
potential significance that the M mRNA of PIV5 appears to be
more sensitive than NP mRNA to inhibition by IFIT1, and fur-
thermore, translation inhibition of PIV5 M mRNA was not res-
cued by treatment with CMTR1. The differences in the relative
sensitivity of the NP andMmRNAs clearly warrant further inves-
tigation butmay be due to the fact that the viral methyltransferase
differentially methylates the viral mRNAs (as has been shown for
vesicular stomatitis virus [VSV] [48]), that CMTR1 does not rec-
ognize the untranslated region (UTR) of the PIV5 M mRNA, or
that inhibition by IFIT1 is influenced by additional structural fea-
tures present onPIV5MmRNAbut notNPmRNA.Regarding the
latter point, it is of note that the first three nucleotides of theUTRs
of NP and M differ. Furthermore, the 4 or 5 nucleotides down-
stream of cap 0 are thought to be bound by IFIT1 and may thus
modulate IFIT1-RNA interactions (49), and some secondaryRNA
structures, e.g., those found at the 5= end of some alphaviruses, can
prevent IFIT1 binding to RNA independent of the cap methyl-
ation status (50).
Most viruses successfully avoid inhibition by IFIT1 by encod-
ing their own 2=-OMTase, by cap snatching appropriately capped
and 2=-O methylated structures from cellular mRNAs, or by hav-
ing cap-independent translation with the covalently linked viral
protein VPg or a 5= RNA secondary structure that blocks the ac-
tivity of IFIT1 (reviewed in reference 26). Indeed, work on virus
restriction by IFIT1 has involved primarily the investigation of
viruses in which the 2=-O-MTases have been mutated such that
their mRNAs do not have a cap 1 structure (25, 51–54). Neverthe-
less, our results show that the viral polymerase of rubulaviruses,
unlike other paramyxoviruses, does not fully protect the viral
mRNAs from inhibition by human IFIT1. In this regard, it is of
interest that although rubulaviruses have the conserved methyl-
transferase domain in their polymerase, they all have an alanine
instead of the first glycine in a GxGxG motif present in the meth-
yltransferase domain of other paramyxoviruses andmononegavi-
rales, which has been shown to affect the efficiency of cap meth-
ylation (55).
Most viruses, including other mononegavirales (56), appear to
be naturally resistant to inhibition by IFIT1. It is therefore intrigu-
ing that rubulaviruses have not evolved mechanisms to ensure
that theirmRNAs are correctly capped andmethylated or have the
appropriate UTRs to be resistant to IFIT1. It is tempting to spec-
ulate that there is some unknown biological advantage to being
sensitive to IFIT1. For example, it may help some rubulaviruses
(and perhaps hepatitis C virus [57], which is also sensitive to
IFIT1) to establish prolonged or persistent infections. Thus, fol-
lowing infection of cells in an IFN-induced antiviral state, IFIT1
restricts PIV5 replication. Under such conditions, virus genomes
are located in cytoplasmic foci, where, as we have previously sug-
gested, they may remain hidden from intracellular and adaptive
immune responses. Furthermore, if viral mRNA is produced in
cells in an IFN-induced antiviral state, then viral protein synthesis
will largely be inhibited by IFIT1, thus reducing the amount of
protein that may be processed and presented to cytotoxic T lym-
phocytes (CTLs). Eventually, in such cells, however, enough of the
virus IFN antagonist, the V protein, will be produced or brought
in by infecting virus particles to target STAT1 for proteasome-
mediated degradation, and the cells will no longer be able tomain-
tain their antiviral state, thus facilitating virus replication (58).
Whether such a scenario occurs in vivo, these and other consider-
ations emphasize that to fully understand the molecular patho-
genesis of viruses, it will be necessary to understand the subtleties
of how viruses interact with the IFN system and other host cell
defense mechanisms.
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